Hans Hull - 23 Jan 2025 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)

Reporting relationship: Chief Business Officer
Issuer ticker: PLRX
Reported as of: 23 Jan 2025
Net transaction value: $0
SEC form: 4
Accepted by SEC: 27 Jan 2025, 18:07:17 UTC
Prior SEC filing: 22 Jan 2025
Source filing: View source filing
Reporting owner signature: /s/ Jennifer Woo, attorney-in-fact

Key filing fact

Hans Hull filed Form 4 for PLIANT THERAPEUTICS, INC. (PLRX) on 27 Jan 2025.

Key facts

This page summarizes Hans Hull's Form 4 filing for PLIANT THERAPEUTICS, INC. (PLRX).
2 reported transactions and 1 derivative row are listed below.
Accepted by SEC: 27 Jan 2025, 18:07.

Change

Previous filing in this sequence was filed on 22 Jan 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported non-derivative transactions

Shares, units, or other non-derivative securities reported in this filing.

PLRX transaction

Common Stock

Award

Transaction value: $0
Shares: +40,150
Change %: +19%
Price: $0.000000
Shares after: 251,708
Date: 23 Jan 2025
Ownership: Direct
Footnotes: F1

PLRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 3,821
Date: 23 Jan 2025
Ownership: See Footnote
Footnotes: F2

PLRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 13,985
Date: 23 Jan 2025
Ownership: See footnote
Footnotes: F3

PLRX holding

Common Stock

No transaction description listed

Transaction value
Shares
Change %
Price
Shares after: 13,985
Date: 23 Jan 2025
Ownership: See Footnote
Footnotes: F4

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PLRX transaction Derivative

Stock Option (Right to Buy)

Award

Transaction value: $0
Shares: +80,300
Change %
Price: $0.000000
Shares after: 80,300
Date: 23 Jan 2025
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 80,300
Exercise price: $11.14
Footnotes: F5

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 5 footnotes

Footnote F1

These are restricted stock units that vest in three substantially equal annual installments beginning January 16, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.

Footnote F2

The shares are held by The Sloger Hull Family Trust. The Reporting Person and his spouse serve as trustees for the trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Footnote F3

The shares are held by a trust for the Reporting Person's minor child ("Child A Trust"). The Reporting Person and his spouse serve as trustees for Child A Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Footnote F4

The shares are held by a trust for the Reporting Person's minor child ("Child B Trust"). The Reporting Person and his spouse serve as trustees for Child B Trust. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these shares in this report shall not be deemed an admission of beneficial ownership of all of the reported shares for purposes of Section 16 or for any other purpose.

Footnote F5

1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of January 1, 2025, subject to the Reporting Person's continuous service to the Issuer on each such date.